Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema
January 12, 2021 at 08:30 am
Rezolute, Inc. announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME). The study (RZ402-101) is a single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of RZ402 in healthy adult volunteers. The Company expects to complete the study in the first half of 2021.